$695 | Single User
$1395 | Global License

Physician Views: As Tecfidera approaches a critical juncture in Europe, how are neurologist perceptions towards Biogen Idec's MS drug shaping up?
[Lowest Price Guaranteed: $695]

Published by FirstWord Pharma: 01 Nov 2013 | 77 | In Stock
Related Topics: Novartis , Products

Introduction

Scope


Sales of Biogen Idec’s multiple sclerosis therapy Tecfidera may continue to exceed initial expectations in the US market, but in Europe a shadow of doubt has been cast across the future of the drug.



On the company’s Q3 earnings call, management confirmed that the European Medicines Agency's Committee for Medicinal Products for Human Use is expected to make a final decision on regulatory data protection (RDP) for Tecfidera on or shortly after November 22. Biogen Idec is now reportedly looking to secure new active substance (NAS) for the product.



That decision is seen as being critical in determining whether Biogen Idec launches Tecfidera in the EU; in the advent that no RDP is granted, there is a clear rationale for Biogen Idec not to launch the drug, argue analysts, given both the direct threat of short-term generic competition and the indirect impact of said competition on the company's other MS franchises. See ViewPoints: Tecfidera sales soar, but 'all or nothing' EU decision on data exclusivity looms for Biogen Idec.



An exceptional US sales growth performance for Tecfidera is a clear barometer of how this product has been embraced by both neurologists and patients since its launch in April, supported by positive key opinion leader feedback. Similarly, there is evidence to support the view that anticipation among European neurologists is equally high.



When FirstWord polled 138 EU5-based neurologists in June, respondents indicated that on average they were 'warehousing' 12 percent of newly diagnosed MS patients for treatment with Biogen Idec’s oral therapy. Last month, analysts at Leerink Swann informed investors of significant "pent-up demand" for Tecfidera, suggesting that should a launch not materialise on RDP grounds there could be a "community-wide backlash" (see ViewPoints: Delayed launch for Biogen Idec's Tecfidera said to be causing "quasi-hysteria" among European MS patients).


Puchase Reasons


With Tecfidera now approaching what appears to be a critical juncture in Biogen Idec’s European regulatory process, FirstWord is this week polling neurologists based in the EU5 to ascertain how perceptions around Tecfidera have shifted over the past six months. Specifically neurologists will be asked:


  • What percentage of diagnosed relapsing remitting MS patients are you warehousing in anticipation for treatment with Biogen Idec’s Tecfidera?

  • Has this percentage of patients increased or decreased over the past six months and by what percentage?

  • What percentage of patients initially warehoused for treatment with Tecfidera have you subsequently begun treating with an alternative therapy due to Tecfidera’s delayed launch in the EU?

  • Assuming Tecfidera was to launch in early 2014 – what percentage of total (i.e. newly diagnosed and existing) relapsing remitting MS patients would you anticipate treating with the drug in a first-line setting by the end of next year?

  • What percentage of patients currently treated with another oral therapy (i.e. Novartis’ Gilenya or Sanofi’s Aubagio) would you switch to Tecfidera assuming launch of Biogen Idec’s drug in early 2014?

  • Table of Contents
    for Physician Views: As Tecfidera approaches a critical juncture in Europe, how are neurologist perceptions towards Biogen Idec's MS drug shaping up?

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    77 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: As Tecfidera approaches a critical juncture in Europe, how are neurologist perceptions towards Biogen Idec's MS drug shaping up? | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...